New Drug Launch: Transforming Cardiometabolic Care in India
Glenmark Pharmaceuticals Ltd, a prominent global pharmaceutical company, has expanded its cardiometabolic portfolio by launching Empagliflozin and its fixed-drug combinations in India.
Glenmark Pharmaceuticals Ltd, a prominent global pharmaceutical company, has expanded its cardiometabolic portfolio by launching Empagliflozin and its fixed-drug combinations in India. The newly introduced medications, branded as Glempa, Glempa-L, and Glempa-M, aim to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) and reduce cardiovascular risks. Empagliflozin, a well-established SGLT2 inhibitor, has demonstrated significant benefits, including weight loss and reduced cardiovascular and renal risks in T2DM patients.
The Glempa range offers three treatment options to cater to diverse patient needs. Glempa serves as a standalone SGLT2 inhibitor, Glempa-L combines Empagliflozin with Linagliptin for dual-action therapy, and Glempa-M pairs Empagliflozin with Metformin for enhanced glycemic control. Clinical studies have highlighted the effectiveness of these combinations, showing significant reductions in HbA1c levels, weight, and fasting blood sugar.
Glenmark's commitment to providing innovative and accessible treatments is reflected in the launch of the Glempa range, which aims to offer affordable, high-quality solutions to manage T2DM with cardiovascular disease. The company continues to strengthen its presence in the cardiometabolic care segment, addressing the rising prevalence of diabetes and cardiovascular diseases in India.
DSIJ's 'Large Rhino' service recommends blue chip stocks of Large Cap companies that have leadership positions in their category. If this interests you, do download the service details here.
Company Overview
Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company with a strong presence in branded, generic and OTC segments. The company's focus areas include cardiometabolic, respiratory, dermatology, and oncology. Glenmark operates 11 manufacturing facilities across four continents and is active in over 80 countries. As of the latest data, the company's stock is priced at Rs 1380.75, with a market capitalisation of over Rs 39,000 crore. Over the past year, Glenmark's stock has delivered a return of 46.55 per cent and over three years, it has achieved a return of 208.95 per cent, classifying it as a multibagger stock.
Disclaimer: The article is for informational purposes only and not investment advice.